Apellis Pharmaceuticals Inc (NASDAQ: APLS) is -36.22% lower on its value in year-to-date trading and has touched a low of $33.49 and a high of $73.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The APLS stock was last observed hovering at around $39.60 in the last trading session, with the day’s loss setting it -1.42%.
Currently trading at $38.18, the stock is 2.05% and 0.27% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.98 million and changing -3.59% at the moment leaves the stock -25.22% off its SMA200. APLS registered -11.15% loss for a year compared to 6-month loss of -40.39%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.68% gain in the last 1 month and extending the period to 3 months gives it a -7.13%, and is -4.20% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.85% over the week and 5.52% over the month.
Apellis Pharmaceuticals Inc (APLS) has around 706 employees, a market worth around $4.65B and $628.79M in sales. Fwd P/E is 175.94. Profit margin for the company is -52.94%. Distance from 52-week low is 14.00% and -48.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-45.44%).
The EPS is expected to grow by 71.29% this year
381.0 institutions hold shares in Apellis Pharmaceuticals Inc (APLS), with institutional investors hold 113.25% of the company’s shares. The shares outstanding are 119.56M, and float is at 100.94M with Short Float at 16.12%. Institutions hold 97.08% of the Float.
The top institutional shareholder in the company is WELLINGTON MANAGEMENT GROUP LLP with over 16.39 million shares valued at $628.67 million. The investor’s holdings represent 13.3288 of the APLS Shares outstanding. As of 2024-06-30, the second largest holder is ECOR1 CAPITAL, LLC with 11.61 million shares valued at $445.26 million to account for 9.4402 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 11.11 million shares representing 9.0366 and valued at over $426.22 million, while VANGUARD GROUP INC holds 7.978 of the shares totaling 9.81 million with a market value of $376.29 million.
Apellis Pharmaceuticals Inc (APLS) Insider Activity
The most recent transaction is an insider sale by Dunlop A. Sinclair, the company’s Director. SEC filings show that Dunlop A. Sinclair sold 37,000 shares of the company’s common stock on Jun 21 ’24 at a price of $39.24 per share for a total of $1.45 million. Following the sale, the insider now owns 0.14 million shares.
Apellis Pharmaceuticals Inc disclosed in a document filed with the SEC on May 08 ’24 that Deschatelets Pascal (Chief Scientific Officer) sold a total of 78,907 shares of the company’s common stock. The trade occurred on May 08 ’24 and was made at $42.35 per share for $3.34 million. Following the transaction, the insider now directly holds 1.12 million shares of the APLS stock.
Still, SEC filings show that on Apr 08 ’24, Deschatelets Pascal (Chief Scientific Officer) disposed off 69,107 shares at an average price of $54.17 for $3.74 million. The insider now directly holds 1,115,983 shares of Apellis Pharmaceuticals Inc (APLS).
